



#240-21

**Commonwealth of Virginia
Virginia Department of Education
Superintendent's Memo #240-21**

DATE: August 27, 2021
TO: Division Superintendents
FROM: James F. Lane, Ed.D., Superintendent of Public Instruction
SUBJECT: **FY22 State Funding for Purchase of Albuterol and Valved Holding Chambers for Virginia Public Schools**

The 2021 Appropriation Act (i.e., Chapter 552) includes \$120,000 in one-time state funding in fiscal year 2022 to support the purchase of albuterol and valved holding chambers in Virginia public schools. The passage of [House Bill 2019 at the 2021 Special Session I of the General Assembly](#) requires, effective January 1, 2022, undesignated stock albuterol inhalers to be maintained in every Virginia public school. The Department of Education, in conjunction with the Department of Health and other stakeholders, is developing guidelines for dissemination later this fall on the administration of stock albuterol in public schools.

The \$120,000 in fiscal year 2022 state funding will be distributed to school divisions as a one-time payment to support the requirements in HB 2019. School divisions will receive the one-time payment of state funds by September 30, 2021. As directed by the General Assembly, school division funding amounts will be based on the total number of school buildings in the division, or approximately \$61.89 in funding per school building. **Attachment A** shows the fiscal year 2022 funding amounts by school division.

School Policy and Guidance documents related to HB2019 and required training of school personnel will be available this fall.

For more information

For questions related to the state funding distribution, please email doebudgetoffice@doe.virginia.gov. For questions related to the requirements in HB 2019 or the new state guidelines, please contact Tracey White, School Health Nurse Specialist, at tracy.white@doe.virginia.gov.

JFL/KCD/cle

- A. Attachment: [FY22 Albuterol and Valved Holding Chamber Program State Payments FY 2022](#) (XLSX)